CIK 0001711279 · Large accelerated filer
Krystal Biotech, Inc.
Sign in to watch- Ticker
- KRYS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 821080209
- Phone
- (412) 586-5830
- Business address
- 2100 WHARTON STREET, SUITE 701, PITTSBURGH, PA, 15203
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $17,966,069
- in 2 filings, $18.0M under 10b5-1 plans
Net −$17,966,069. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-04-17 | Krishnan Suma President, R&D | Sale 10b5-1 | −9,724 | $88.41 | $860K | 1,714,188 |
| 2023-04-17 | Krishnan Suma President, R&D | Sale 10b5-1 | −500 | $89.12 | $45K | 1,713,688 |
| 2023-04-17 | Krishnan Krish S President and CEO | Sale 10b5-1 | −1,050 | $85.55 | $90K | 1,733,288 |
| 2023-04-17 | Krishnan Krish S President and CEO | Sale 10b5-1 | −4,298 | $86.80 | $373K | 1,728,990 |
| 2023-04-17 | Krishnan Krish S President and CEO | Sale 10b5-1 | −9,428 | $87.41 | $824K | 1,719,562 |
| 2023-04-17 | Krishnan Krish S President and CEO | Sale 10b5-1 | −9,724 | $88.41 | $860K | 1,709,838 |
| 2023-04-17 | Krishnan Krish S President and CEO | Sale 10b5-1 | −500 | $89.12 | $45K | 1,709,338 |
| 2023-04-17 | Krishnan Krish S President and CEO | Sale 10b5-1 | −1,050 | $85.55 | $90K | 1,676,213 |
| 2023-04-17 | Krishnan Krish S President and CEO | Sale 10b5-1 | −4,297 | $86.80 | $373K | 1,671,916 |
| 2023-04-17 | Krishnan Krish S President and CEO | Sale 10b5-1 | −9,429 | $87.41 | $824K | 1,662,487 |
| 2023-04-17 | Krishnan Krish S President and CEO | Sale 10b5-1 | −9,724 | $88.41 | $860K | 1,652,763 |
| 2023-04-17 | Krishnan Krish S President and CEO | Sale 10b5-1 | −500 | $89.12 | $45K | 1,652,263 |
| 2023-03-31 | Mazzacco Catherine Director | Grant or award · Stock Option (Right to Buy) | +13,600 | 13,600 | ||
| 2023-03-01 | ROSSI DINO A Director | Sale | −40,000 | $83.25 | $3.3M | 83,691 |
| 2023-02-28 | ORTH ANDREW C. Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2023-02-28 | ORTH ANDREW C. Chief Commercial Officer | Grant or award · Performance Stock Units | +10,000 | 10,000 | ||
| 2023-02-28 | Romano Kathryn Chief Accounting Officer | Grant or award · Stock Option (Right to Buy) | +20,000 | 20,000 | ||
| 2023-02-28 | Romano Kathryn Chief Accounting Officer | Grant or award · Performance Stock Units | +10,000 | 10,000 | ||
| 2023-02-28 | Krishnan Suma President, R&D | Grant or award · Stock Option (Right to Buy) | +30,000 | 30,000 | ||
| 2023-02-28 | Krishnan Suma President, R&D | Grant or award · Performance Stock Units | +15,000 | 15,000 |
Page 32 of 42 · 828 trades